The road to Amicus Therapeutics’ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs and a months-long push to settle a legal dispute. The details are included in a new regulatory document that outlines the deal’s history and the run-up to the eventual $ 14.50-a-share price for the Princeton, NJ-based biotech. Amicus had been considering strategic alternatives since at least 2013, when it engaged Goldman Sachs to look at potential deals, according to the SEC filing.
Read the full article: Amicus Reveals It Had Another Suitor Before Reaching $4.8B Sale to BioMarin //
Source: https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/